网红“神药”更新说明书：可能影响性功能 很多学生在用…

Core Viewpoint - The recent announcement by the National Medical Products Administration (NMPA) regarding the revision of the isotretinoin capsule instructions highlights the growing concerns over the drug's side effects, particularly its potential impact on mental health and sexual function, amidst a surge in acne treatment demand during the winter break [1][2]. Group 1: Drug Overview and Usage - Isotretinoin, commonly referred to as "EVA," has gained popularity as an acne treatment among young people, often promoted on social media for its effectiveness while downplaying its side effects [2][3]. - The drug is available in both oral capsule and topical cream forms, and it has been a key medication for treating severe nodular acne since its introduction in the U.S. and Europe in 1982 [3][4]. Group 2: Side Effects and Regulatory Actions - The revised instructions for isotretinoin now include a comprehensive list of adverse reactions, such as endocrine, digestive, mental, and reproductive issues, emphasizing the need for careful monitoring of patients [2][6]. - Reports of adverse reactions globally include 394 cases of depression and 37 suicide incidents in the U.S. from 1982 to 2000, and 14 cases of sexual dysfunction in the UK from 1985 to 2017 [4][5]. - The Australian Therapeutic Goods Administration has mandated that all isotretinoin products include new safety information regarding emotional changes and risks of sexual dysfunction by April 2025 [5]. Group 3: Recommendations and Patient Management - Medical professionals emphasize that isotretinoin should only be used under the supervision of qualified healthcare providers, and many mild acne cases can be treated with safer alternatives [5][6]. - The NMPA's warning encourages patients to consider safer, appropriate, and effective treatment options rather than risking the use of isotretinoin [5].